Setting-up of an internal multidisciplinary Vehicle Working Group to increase knowledge on excipients and recommend their use in preclinical in vivo studies
This poster explores UCB's implementation of a Vehicle Working Group to increase internal knowledge on excipients and recommend use in preclinical studies. But why is this important?
- Enabling formulations for preclinical in vivo studies play a key role for assessing safety, pharmacodynamics, and pharmacokinetics (PK) endpoints of new molecules.
- Excipients used in formulations should maximize exposure while avoiding side effects that could influence experimental results
- As new chemical entities are not always sufficiently soluble and/or bioavailable in commonly used vehicles, ‘exotic cocktails’ of various excipients are often used to prepare preclinical formulations
- Limited information has been published on the potential impact of these excipients on commonly used laboratory animals.
Poster present by Annie Delaunois at the 2014 Safety Pharmacology Society Meeting, Washington, USA; 19th - 22nd October 2014.